Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Institute of Computer Science, University of Tartu, Tartu, Estonia.
PLoS One. 2022 Jun 16;17(6):e0270192. doi: 10.1371/journal.pone.0270192. eCollection 2022.
COVID-19 pandemic has led to overloading of health systems all over the world. For reliable risk stratification, knowledge on factors predisposing to SARS-CoV-2 infection and to severe COVID-19 disease course is needed for decision-making at the individual, provider, and government levels. Data to identify these factors should be easily obtainable.
Retrospective cohort study of nationwide e-health databases in Estonia. We used longitudinal health records from 66,295 people tested positive for SARS-CoV-2 RNA from 26 February 2020 to 28 February 2021 and 254,958 randomly selected controls from the reference population with no known history of SARS-CoV-2 infection or clinical COVID-19 diagnosis (case to control ratio 1:4) to predict risk factors of infection and severe course of COVID-19. We analysed sociodemographic and health characteristics of study participants. The SARS-CoV-2 infection risk was slightly higher among women, and was higher among those with comorbid conditions or obesity. Dementia (RRR 3.77, 95%CI 3.30⎼4.31), renal disease (RRR 1.88, 95%CI 1.56⎼2.26), and cerebrovascular disease (RRR 1.81, 95%CI 1.64⎼2.00) increased the risk of infection. Of all SARS-CoV-2 infected people, 92% had a non-severe disease course, 4.8% severe disease (requiring hospitalisation), 1.7% critical disease (needing intensive care), and 1.5% died. Male sex, increasing age and comorbid burden contributed significantly to more severe COVID-19, and the strength of association for male sex increased with the increasing severity of COVID-19 outcome. The strongest contributors to critical illness (expressed as RRR with 95% CI) were renal disease (7.71, 4.71⎼12.62), the history of previous myocardial infarction (3.54, 2.49⎼5.02) and obesity (3.56, 2.82⎼4.49). The strongest contributors to a lethal outcome were renal disease (6.48, 3.74⎼11.23), cancer (3.81, 3.06⎼4.75), liver disease (3.51, 1.36⎼9.02) and cerebrovascular disease (3.00, 2.31⎼3.89).
We found divergent effect of age and gender on infection risk and severity of COVID-19. Age and gender did not contribute substantially to infection risk, but did so for the risk of severe disease Co-morbid health conditions, especially those affecting renin-angiotensin system, had an impact on both the risk of infection and severe disease course. Age and male sex had the most significant impact on the risk of severe COVID-19. Taking into account the role of ACE2 receptors in the pathogenesis of SARS-CoV-2 infection, as well as its modulating action on the renin-angiotensin system in cardiovascular and renal diseases, further research is needed to investigate the influence of hormonal status on ACE2 expression in different tissues, which may be the basis for the development of COVID-19 therapies.
COVID-19 大流行导致全球卫生系统不堪重负。为了进行可靠的风险分层,需要了解导致 SARS-CoV-2 感染和严重 COVID-19 病程的因素,以便在个人、提供者和政府层面做出决策。应该能够方便地获取用于识别这些因素的数据。
在爱沙尼亚全国电子健康数据库中进行回顾性队列研究。我们使用了从 2020 年 2 月 26 日至 2021 年 2 月 28 日对 66295 名 SARS-CoV-2 RNA 检测呈阳性的人的纵向健康记录,以及来自没有 SARS-CoV-2 感染或临床 COVID-19 诊断史的参考人群的 254958 名随机选择的对照(病例与对照的比例为 1:4),以预测感染的危险因素和 COVID-19 的严重病程。我们分析了研究参与者的社会人口统计学和健康特征。女性感染 SARS-CoV-2 的风险略高,并且在患有合并症或肥胖的人群中风险更高。痴呆症(RRR 3.77,95%CI 3.30-4.31)、肾脏疾病(RRR 1.88,95%CI 1.56-2.26)和脑血管疾病(RRR 1.81,95%CI 1.64-2.00)增加了感染的风险。在所有 SARS-CoV-2 感染者中,92%的人患有非严重疾病,4.8%患有严重疾病(需要住院治疗),1.7%患有危急疾病(需要重症监护),1.5%死亡。男性、年龄增长和合并症负担显著增加了 COVID-19 的严重程度,而男性与 COVID-19 严重程度之间的关联强度随着 COVID-19 结局的严重程度而增加。导致危重病(用 95%CI 表示的 RRR)的最强因素是肾脏疾病(7.71,4.71-12.62)、既往心肌梗死史(3.54,2.49-5.02)和肥胖(3.56,2.82-4.49)。导致致命结局的最强因素是肾脏疾病(6.48,3.74-11.23)、癌症(3.81,3.06-4.75)、肝脏疾病(3.51,1.36-9.02)和脑血管疾病(3.00,2.31-3.89)。
我们发现年龄和性别对 COVID-19 的感染风险和严重程度有不同的影响。年龄和性别对感染风险没有显著影响,但对严重疾病的风险有显著影响。合并症健康状况,特别是影响肾素-血管紧张素系统的健康状况,对感染风险和严重疾病病程都有影响。年龄和男性对严重 COVID-19 的风险影响最大。考虑到 ACE2 受体在 SARS-CoV-2 感染发病机制中的作用,以及其在心血管和肾脏疾病中对肾素-血管紧张素系统的调节作用,需要进一步研究荷尔蒙状态对不同组织中 ACE2 表达的影响,这可能是 COVID-19 治疗的基础。